Cmc Biologics

UPDATE

CMC Biologics to make Harpoon’s cancer drugs in California, US

15-Dec-2017 By Flora Southey

Harpoon Therapeutics has selected CMC Biologics to develop and manufacture three molecules for cancer treatments at the CDMO’s facilities in California and Washington State, US.

Trellis selects CMC Biologics to make mAb therapies

08-Aug-2017 By Flora Southey

CMC Biologics and Trellis Bioscience are teaming up to make monoclonal antibody (mAb)-based therapies.

AGC expanding CDMO biz through $500m CMC Biologics buy

21-Dec-2016 By Dan Stanton

AGC Asahi Glass has signed an agreement to buy CMC Biologics, the second biologics CDMO acquisition for the Japanese chemicals firm in three months.

Catalent’s CHO cell lines and Gate’s Foundation to make PATH Malaria vaccine

21-Dec-2016 By Dani Bancroft

Catalent has partnered with US non-profit PATH for antibody discovery using the CDMO’s GPEx cell line platform, funded by PATH’s Malaria Vaccine Initiative (MVI).

Breaking the single-use paradigm? CMC Biologics to offer 12,000L scale runs

03-Jun-2016 By Dan Stanton

Single-use manufacturing runs have been limited to 2,000L, but CMC Biologics says it will be able to offer 12,000L of commercial scale through its bioreactor configuration platform.

CMC Biologics to manufacture Zymeworks antibody

05-Sep-2014 By Zachary Brennan

Contract manufacturer CMC Biologics and Zymeworks have entered into a master services agreement whereby CMC will perform the process development, formulation development and cGMP clinical manufacturing of a recombinant human IgG1 bi-specific (heterodimeric)...